The National Agency for Food and Drug Administration and Control (NAFDAC) has reaffirmed that medicines and vaccines supplied to Nigeria under government-to-government agreements will remain subject to regulatory oversight, including quality, safety and efficacy assessments.
The National Agency for Food and Drug Administration and Control (NAFDAC) has assured Nigerians that medicines and vaccines entering the country under the United States Government–Government of Nigeria (USG–GoN) agreement will not be exempted from regulatory scrutiny.
In a press release issued on 20 October 2026, the agency reiterated that all medical products supplied under the agreement must meet the required standards before and during distribution. The assurance comes amid efforts to sustain access to essential medicines, particularly those supporting HIV/AIDS services, following the exit of the United States Agency for International Development (USAID).
NAFDAC's position reinforces its statutory responsibility to protect public health by ensuring that medical products available to Nigerians meet established quality, safety and efficacy requirements, regardless of their source of supply.
NAFDAC Retains Regulatory Authority
According to the agency, the Coordinating Minister of Health and Social Welfare, Prof. Ali Pate, has reiterated that NAFDAC retains its statutory mandate to regulate medicines, vaccines and diagnostics supplied under the agreement.
This responsibility includes product evaluation, facility inspections, risk-based testing, vaccine lot release and post-market surveillance, where required. These regulatory measures are intended to ensure that medical products meet the necessary standards and that potential quality or safety concerns can be identified and addressed.
The agency's clarification underscores that government-to-government arrangements do not override Nigeria's existing regulatory framework or diminish NAFDAC's authority to make decisions concerning products entering the Nigerian market.
Expedited Review for US-Approved Products
NAFDAC explained that the regulatory-reliance framework referenced in the agreement may allow products manufactured in the United States and approved by the US Food and Drug Administration (FDA) to undergo an expedited review.
This approach recognises the established regulatory processes of the FDA while allowing NAFDAC to consider relevant assessments already conducted by the US regulator. However, an expedited review does not constitute an automatic exemption from Nigerian regulatory requirements.
Products manufactured outside the United States will undergo NAFDAC's full quality, safety and efficacy testing, according to the agency's statement. NAFDAC also emphasised that regulatory reliance does not transfer its decision-making authority to another regulator.
Track and Trace System to Monitor Distribution
Beyond product assessment, NAFDAC will deploy its GS1-based Track and Trace system to monitor the supply and distribution of products covered by the agreement.
The system records distribution activities through the agency's Traceability Information System (TIS), supporting visibility across the supply chain. According to the release, the system was used to monitor COVID-19 vaccines during the pandemic and has since expanded to cover non-COVID-19 vaccines and selected commodities, including narcotics and maternal and newborn health products.
Effective traceability can help strengthen supply-chain oversight, support the identification of products and their distribution pathways, and facilitate investigations when suspected quality defects or other safety concerns arise.
Implications for Pharmacists and Public Health
The assurance is particularly relevant to pharmacists and other healthcare professionals involved in medicine procurement, storage, dispensing and patient counselling. Donated medicines and externally supplied health commodities must meet appropriate quality standards to protect patients and maintain confidence in the healthcare system.
For pharmacists, supply-chain traceability can complement pharmacovigilance activities by helping to identify affected products and support appropriate responses when adverse events, suspected substandard medicines or other product-related concerns are reported.
Healthcare professionals also have a role in ensuring that medicines are obtained through authorised supply channels, stored under the required conditions and dispensed appropriately. Patients and healthcare providers should report suspected adverse reactions or product quality concerns through the relevant reporting channels.
NAFDAC's position is that the origin of a medical product does not remove the need for regulatory safeguards. Maintaining effective oversight is essential to ensuring that externally supplied medicines and vaccines contribute to healthcare delivery without compromising patient safety.
Commitment to Safeguarding Public Health
The press release, signed by NAFDAC Director-General and Chief Executive Officer, Prof. Mojisola Adeyeye, reaffirmed the agency's commitment to protecting public health by ensuring that medical products supplied to Nigerians meet the required standards.
As Nigeria continues to engage in international health partnerships and medicine-supply arrangements, the effectiveness of regulatory oversight, product traceability and post-market monitoring will remain important to safeguarding patients and sustaining public confidence in the country's healthcare system.
Social Plugin